microRNAs and recurrent hepatocellular carcinoma

doi:10.3760/cma.j.issn.1673-422X.2015.10.018

Abstract

Abstract: microRNAs (miRNAs) play important roles in recurrent hepatocellular carcinoma by regulating translation of target gene expression. Researches show that the abnormal expressions of miRNAs are closely related to the recurrent hepatocellular carcinoma, and the mechanisms include regulation of tumor angiogenesis and proliferation of tumor cells. miRNAs may be the most potential therapeutic targets for recurrent hepatocellular carcinoma and have special advantages in prediction.

Key words: MicroRNAs, Liver neoplasms, Recurrence

Ma Chenyang, Hu Minghua. microRNAs and recurrent hepatocellular carcinoma[J]. Journal of International Oncology, 2015, 42(10): 783-785.

References

［1］ Schoof CR, Botelho EL, Izzotti A, et al. MicroRNAs in cancer treatment and prognosis［J］. Am J Cancer Res, 2012, 2(4): 414-433. ［2］ Lanford RE, HildebrandtEriksen ES, Petri A, et al. Therapeutic silencing of microRNA122 in primates with chronic hepatitis C virus infection［J］. Science, 2010, 327(5962): 198-201. ［3］ Thibault PA, Huys A, Dhillon P, et al. MicroRNA122dependent and independent replication of Hepatitis C Virus in Hep3B human hepatoma cells［J］. Virology, 2013, 436(1): 179-190. ［4］ Qiu L, Fan H, Jin W, et al. miR-122induced down-regulation of HO-1 negatively affects miR-122mediated suppression of HBV［J］. Biochem Biophys Res Commun, 2010, 398(4): 771-777. ［5］ Wang S, Qiu L, Yan X, et al. Loss of microRNA-122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity［J］. Hepatology, 2012, 55(3): 730-741. ［6］ Roderburg C, Urban GW, Bettermann K, et al. MicroRNA profiling reveals a role for miR-29 in human and murine liver fibrosis［J］. Hepatology, 2011, 53(1): 209-218. ［7］ Jung CJ, Iyengar S, Blahnik KR, et al. Human ESC selfrenewal promoting microRNAs induce epithelialmesenchymal transition in hepatocytes by controlling the PTEN and TGFβ tumor suppressor signaling pathways［J］. Mol Cancer Res, 2012, 10(7): 979-991. ［8］ Venugopal SK, Jiang J, Kim TH, et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation［J］. Am J Physiol Gastrointest Liver Physiol, 2010, 298(1): G101-G106. ［9］ Toffanin S, Sia D, Villanueva A. microRNAs: new ways to block tumor angiogenesis?［J］. J Hepatol, 2012, 57(3): 490-491. ［10］ Yang X, Zhang XF, Lu X, et al. MicroRNA26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factorcMet pathway［J］. Hepatology, 2014, 59(5): 1874-1885. ［11］ Shih TC, Tien YJ, Wen CJ, et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatomaderived growth factor in human hepatoma［J］. J Hepatol, 2012, 57(3): 584-591. ［12］ Wang R, Zhao N, Li S, et al. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42［J］. Hepatology, 2013, 58(2): 642-653. ［13］ Fang JH, Zhou HC, Zeng C, et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression［J］. Hepatology, 2011, 54(5): 1729-1740. ［14］ Xia H, Ooi LL, Hui KM. MiR-214 targets β-catenin pathway to suppress invasion, stemlike traits and recurrence of human hepatocellular carcinoma［J］. PLoS One, 2012, 7(9): e44206. ［15］ Xia H, Ooi LL, Hui KM. MicroRNA-216a/217induced epithelialmesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer［J］. Hepatology, 2013, 58(2): 629-641. ［16］ Yang Z, Miao R, Li G, et al. Identification of recurrence related microRNAs in hepatocellular carcinoma after surgical resection［J］. Int J Mol Sci, 2013, 14(1): 1105-1118. ［17］ Chung GE, Yoon JH, Myung SJ, et al. High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma［J］. Oncol Rep, 2010, 23(1): 113-119. ［18］ Utsunomiya T, Ishikawa D, Asanoma M, et al. Specific miRNA expression profiles of nontumor liver tissue predict a risk for recurrence of hepatocellular carcinoma［J］. Hepatol Res, 2014, 44(6): 631-638. ［19］ Sato F, Hatano E, Kitamura K, et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria［J］. PLoS One, 2011, 6(1): e16435. ［20］ Zhu HT, Dong QZ, Sheng YY, et al. MicroRNA-29a5p is a novel predictor for early recurrence of hepatitis B virusrelated hepatocellular carcinoma after surgical resection［J］. PLoS One, 2012, 7(12): e52393. ［21］ Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma［J］. Hepatology, 2010, 51(3): 836-845.

[1]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[3]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[4]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong. Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells [J]. Journal of International Oncology, 2023, 50(9): 513-519.
[7]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[8]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[9]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[10]	Li Jiaxuan, Feng Yinglu. Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells [J]. Journal of International Oncology, 2023, 50(4): 241-243.
[11]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin. Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(2): 117-121.
[12]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[13]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke. Diagnostic value of serum TIM-3 in patients with liver cancer [J]. Journal of International Oncology, 2022, 49(9): 537-542.
[14]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472.
[15]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.